Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01367301 · OUTCOME

Recurrence-free Survival

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer · Source last updated 2023-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Date of entry to date of reappearance of disease, assessed at 1 year

What was measured

One-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution.

Analysis population: Recurrence-free survival data was not collected/aggregated and therefore not analyzed.

Groups in this outcome

Treatment (Paclitaxel, Carboplatin, Radiotherapy)

CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22. RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16. paclitaxel: Given IV carboplatin: Given IV external beam radiation therapy: Undergo external beam radiation therapy brachytherapy: Undergo HDR brachytherapy intensity-modulated radiation therapy: Undergo IMRT laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Paclitaxel, Carboplatin, Radiotherapy)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
One-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution.
groups
  1. description
    CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22. RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16. paclitaxel: Given IV carboplatin: Given IV external beam radiation therapy: Undergo external beam radiation therapy brachytherapy: Undergo HDR brachytherapy intensity-modulated radiation therapy: Undergo IMRT laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (Paclitaxel, Carboplatin, Radiotherapy)
population Description
Recurrence-free survival data was not collected/aggregated and therefore not analyzed.
reporting Status
POSTED
time Frame
Date of entry to date of reappearance of disease, assessed at 1 year
title
Recurrence-free Survival
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice